Toward rational therapy for mantle cell lymphoma

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

(2023) Salomé Decombis et al.   BLOOD

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

(2021) Anita Kumar et al.   BLOOD

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

(2020) Steven Le Gouill et al.   BLOOD

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

(2018) Constantine S. Tam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

(2018) Rishu Agarwal et al.   NATURE MEDICINE

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

(2016) D. Chiron et al.   BLOOD